Your immune system usually works like a very underfunded but surprisingly effective security team. It spots trouble, tackles infected cells, and occasionally saves your life without asking for applause. But it also employs regulatory T cells, or Tregs, whose job is to stop the rest of the immune system from smashing up the furniture. In healthy tissue, that is a gift. In cancer, it can turn into a scam.
Tumors love Tregs. They recruit them, feed them, and give them the sort of workplace perks most humans can only dream about. Once settled in the tumor microenvironment, Tregs suppress the immune cells that might otherwise attack the cancer. Think of them as bouncers who somehow got hired by the criminals.
That is the setup behind this 2026 review by Xie, Hamdy, and Elkord. Their point is simple: checkpoint drugs like anti-PD-1 and anti-CTLA-4 changed cancer care, but many tumors still shrug and carry on. One reason is that Tregs keep the neighborhood friendly for cancer even when checkpoints get blocked [1].
Beyond the usual suspects
Older Treg-targeting ideas focused heavily on checkpoint molecules. The problem is that tumors are not one-trick villains. If you block one suppressive pathway, they often keep several backup generators humming.
This review maps the newer strategy space. Instead of only hitting checkpoints, researchers are now targeting IL-2/CD25 signaling, TGF-beta, FOXP3, the CD39/CD73 adenosine pathway, and chemokine receptors like CCR4 and CCR8 that help Tregs get into tumors and stay there [1]. In plain English: do not just argue with the security guard at the door. Cut off the radio, the payroll, the rideshare app, and maybe the secret tunnel too.
That shift makes sense because Tregs are not generic across all tissues. A breast tumor, pancreatic tumor, and melanoma do not run their immune suppression in exactly the same way. Biology, like real estate, remains obsessed with location. The same species can solve similar problems with bizarrely different anatomy - bats fly with hands, whales swim with modified legs, and tumors across organs all seem to invent their own version of "please ignore me, immune system."
Tumors feed the referees
One of the nastier insights in this field is that tumors do not merely attract Tregs. They help power them.
A 2021 Nature paper showed that lactic acid in tumors can metabolically support tumor-infiltrating Tregs [2]. Then a 2022 Cancer Cell study found that lactic acid can push PD-1 expression on Tregs in highly glycolytic tumors, which may help explain why PD-1 blockade does not always produce the heroic movie ending people want [3]. Tumors are basically leaving out sports drinks for the cells that suppress anti-cancer immunity. Rude, honestly.
Other work shows the same pattern from another angle: intratumoral Tregs can promote CD8 T cell exhaustion, the immunologic equivalent of getting locked into a group project with three vampires and no coffee [4]. So if you want killer T cells to do their job, you may need to weaken the local Treg machinery, not merely wave a checkpoint inhibitor at the problem and hope for cinematic music.
The trick is not causing friendly fire
Here is the catch, and it is a big one. Tregs are not villains everywhere. Wipe them out systemically and you risk autoimmune toxicity, because now the immune system may decide your colon, skin, or endocrine glands look suspicious. That is less "precision oncology" and more "release the raccoons into the pantry."
So the field is trying to get picky. The dream is to target Tregs enriched inside tumors while sparing the ones keeping normal tissues from turning into inflammatory chaos. Reviews from the last few years keep landing on that same theme: better biomarkers, better tumor selectivity, and smarter drug engineering matter as much as the target itself [1,5,6]. CCR8 has attracted attention for exactly this reason, since it appears enriched on tumor-associated Tregs and has already moved into early clinical development [1].
Why this matters outside the lab coat bubble
If these strategies hold up, they could widen the number of patients who benefit from immunotherapy, especially in cancers where checkpoint blockade alone has been disappointing. That includes "cold" tumors where immune cells either do not enter well or arrive only to get smothered by suppressive signals.
The big idea is not to replace checkpoint therapy, but to stop asking it to carry the whole band by itself. Pair it with smarter Treg-directed tools, and you might turn a stalled immune response into one that actually finishes the job. Not guaranteed, of course. Cancer biology still has the energy of a raccoon with a lock-picking set. But this review captures where the field is getting sharper: fewer blunt instruments, more attempts at local, tumor-specific sabotage of immune suppression [1].
References
- Xie J, Hamdy H, Elkord E. Treg-directed cancer immunotherapy beyond immune checkpoints: progress and opportunities. Trends Pharmacol Sci. 2026. DOI: https://doi.org/10.1016/j.tips.2026.03.007
- Watson MJ, Vignali PDA, Mullett SJ, et al. Metabolic support of tumour-infiltrating regulatory T cells by lactic acid. Nature. 2021;591:645-651. DOI: https://doi.org/10.1038/s41586-020-03045-2
- Kumagai S, Togashi Y, Sakai C, et al. Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. Cancer Cell. 2022;40(2):201-218.e9. DOI: https://doi.org/10.1016/j.ccell.2022.01.001
- Zhang L, Veniaminova NA, Shi Y, et al. Spatial and functional targeting of intratumoral Tregs reverses CD8+ T cell exhaustion and promotes cancer immunotherapy. J Clin Invest. 2024;134(14):e180080. DOI: https://doi.org/10.1172/JCI180080
- Iglesias-Escudero M, Arias-González N, Martínez-Cáceres E. Regulatory cells and the effect of cancer immunotherapy. Mol Cancer. 2023;22:26. DOI: https://doi.org/10.1186/s12943-023-01714-0
- Mortezaee K. Selective targeting or reprogramming of intra-tumoral Tregs. Med Oncol. 2024;41(3):71. DOI: https://doi.org/10.1007/s12032-024-02300-0
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.